(a) As used in this section:

Ask a legal question, get an answer ASAP!
Click here to chat with a lawyer about your rights.

(1) “MDMA” means the synthetic psychoactive drug, 3,4-methylenedioxymethamphetamine, commonly known as ecstasy or molly, that acts as a serotonin receptor agonist and reuptake inhibitor of serotonin and dopamine.

(2) “Psilocybin” means a serotonin receptor agonist that occurs naturally in some mushroom species.

(3) “Qualified patient” means a resident of the state who is (A) a veteran, (B) a retired first responder, or (C) a direct care health care worker.

(b) Not later than January 1, 2023, the Department of Mental Health and Addiction Services shall establish, within available appropriations, a psychedelic-assisted therapy pilot program, to be administered by a medical school in the state. Such pilot program shall provide qualified patients with MDMA-assisted or psilocybin-assisted therapy as part of a research program approved by the federal Food and Drug Administration pursuant to 21 C.F.R. § part 312, as amended from time to time. The department shall cease to operate the pilot program when MDMA and psilocybin have been approved to have a medical use by the Drug Enforcement Administration, or any successor agency.